Es­pe­ri­on re­leas­es pos­i­tive PhII re­sults; Safe­ty warn­ings at In­dia, Chi­na man­u­fac­tur­ing sites spell trou­ble for glob­al sup­ply chain

→ Af­ter lin­ing up a new $200 mil­lion fund­ing deal for the pro­ject­ed com­mer­cial launch of be­mpe­doic acid next year, Es­pe­ri­on an­nounced to­day pos­i­tive re­sults from their Phase II ran­dom­ized, dou­ble-blind par­al­lel-group study of be­mpe­doic acid/eze­tim­ibe com­bi­na­tion tablet in com­par­i­son to eze­tim­ibe and place­bo. 179 pa­tients with hy­per­c­ho­les­terolemia and type II di­a­betes were en­rolled. The 12-week study met its pri­ma­ry and sec­ondary end­points.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER